Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.41 - $6.7 $81,499 - $160,130
-23,900 Reduced 32.3%
50,100 $193,000
Q2 2024

Aug 14, 2024

BUY
$4.3 - $8.03 $70,090 - $130,888
16,300 Added 28.25%
74,000 $380,000
Q1 2024

May 15, 2024

BUY
$6.35 - $9.39 $99,695 - $147,423
15,700 Added 37.38%
57,700 $403,000
Q4 2023

Feb 14, 2024

BUY
$5.59 - $9.55 $177,762 - $303,690
31,800 Added 311.76%
42,000 $372,000
Q3 2023

Nov 14, 2023

BUY
$9.5 - $15.07 $96,900 - $153,714
10,200 New
10,200 $97,000

Others Institutions Holding PRME

About Prime Medicine, Inc.


  • Ticker PRME
  • Shares Outstandng 95,730,200
  • Market Cap $315M
More about PRME
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.